Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study

In interim analysis of randomised cohort (n=272 of 371), rates of virological suppression (HIV-1 RNA <40 copies per mL) with fostemsavir-based antiretroviral regimens increased from 53% (144 of 272) at week 24 to 60% (163 of 272) at week 96.

The Lancet HIV